Outcomes of Liver Transplantation for Non-alcoholic Steatohepatitis: a European Liver Transplant Registry Study.

Haldar, Debashis and Kern, Barbara and Hodson, James and James Armstrong, Matthew and Adam, Rene and Berlakovich, Gabriela and Fritz, Josef and Feurstein, Benedikt and Popp, Wolfgang and Karam, Vincent and Muiesan, Paolo and O'Grady, John and Jamieson, Neville and Wigmore, Stephen J and Pirenne, Jacques and Ali Malek-Hosseini, Seyed and Hidalgo, Ernest and Tokat, Yaman and Paul, Andreas and Pratschke, Johann and Bartels, Michael and Trunecka, Pavel and Settmacher, Utz and Pinzani, Massimo and Duvoux, Christophe and Noel Newsome, Philip and Schneeberger, Stefan (2019) Outcomes of Liver Transplantation for Non-alcoholic Steatohepatitis: a European Liver Transplant Registry Study. Journal of hepatology. ISSN 1600-0641. This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs

Full text not available from this repository.
Official URL: https://linkinghub.elsevier.com/retrieve/pii/S0168...

Abstract

BACKGROUND & AIMS

Little is known about outcomes of liver transplantation for patients with non-alcoholic steatohepatitis (NASH). We aimed to determine the frequency and outcomes of liver transplantation for patients with NASH in Europe and identify prognostic factors.

METHODS

We analyzed data from patients transplanted for end-stage liver disease between January 2002 and December 2016 using the European Liver Transplant Registry database. We compared data between patients with NASH versus other etiologies. The principle endpoints were patient and overall allograft survival.

RESULTS

Among 68,950 adults undergoing first liver transplantation, 4.0% were transplanted for NASH - an increase from 1.2% in 2002 to 8.4% in 2016. A greater proportion of patients transplanted for NASH (39.1%) had hepatocellular carcinoma (HCC) than non-NASH patients (28.9%, P<.001). NASH was not significantly associated with survival of patients (HR 1.02, P=.713) or grafts (HR 0.99; P=.815) after accounting for available recipient and donor variables. Infection (24.0%) and cardio/cerebrovascular complications (5.3%) were the commonest causes of death in NASH patients without HCC. Increasing recipient age (61-65 years: HR 2.07, P<.001; >65: HR 1.72, P=.017), elevated MELD (>23: HR 1.48, P=.048) and low (<18.5kg.m: HR 4.29, P=.048) or high (>40kg.m: HR 1.96, P=.012) recipient BMI independently predicted death in patients transplanted for NASH without HCC. Data must be interpreted in the context of absent recognised confounders, such as pre-morbid metabolic risk factors.

CONCLUSIONS

The number and proportion of liver transplants performed for NASH in Europe has increased from 2002 through 2016. HCC was more common in patients transplanted with NASH. Survival of patients and grafts in patients with NASH is comparable to that of other disease indications.

LAY SUMMARY

NASH is a growing indication for liver transplantation in Europe, with good overall outcomes, although careful assessment for risk factors is required to maintain favorable post-transplant outcomes.

Item Type: Article
Additional Information: This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs
Subjects: WI Digestive system. Gastroenterology
Divisions: Planned IP Care > Gastroentrology
Related URLs:
Depositing User: Mrs Yolande Brookes
Date Deposited: 10 May 2019 15:10
Last Modified: 10 May 2019 15:10
URI: http://www.repository.heartofengland.nhs.uk/id/eprint/2097

Actions (login required)

View Item View Item